Financial Performance - Q3 2025 - Sales increased by 2.4% to $853 million compared to Q3 2024[12, 14] - Gross profit rose by 18% to $242 million, with gross margin improving to 28.3% from 24.6%[12, 14] - EBITDA surged by 59% to $97 million, with EBITDA margin increasing to 11.3% from 7.3%[12, 14] - Net loss improved by 69% from -$73 million to -$23 million[12] Financial Performance - 9M 2025 - Sales remained stable at $2,698 million, a decrease of 0.8% compared to 9M 2024[15, 17] - Gross profit increased by 11% to $788 million, with gross margin improving to 29.2% from 26.1%[15, 17] - EBITDA increased by 29% to $341 million, with EBITDA margin improving to 12.6% from 9.7%[15, 17] - Net loss significantly improved from -$142 million to approximately $0 million[15, 17] Regional Performance - 9M 2025 - North America experienced a sales growth of 16% at CER[19] - APAC experienced a sales decline of 14% at CER[19]

Financial Performance - The company's profit attributable to owners increased by 5.1% to RMB 526 billion [13] - Net profit margin increased by 04 percentage points to 93% [13] - Basic earnings per share increased 21% to RMB 10143 cents [95] - The company's dividend per share increased by 30% to HK$ 340 cents [13, 95] - The dividend payout ratio increased by 07 percentage points to 311% [13, 95] - Bank balances and cash increased by 161% to RMB 3320 billion [13] - Net gearing ratio decreased by 84 percentage points to 652% [13, 100] Business Growth and Strategy - New orders value for 2025 H1 increased by 228% year-on-year, excluding a specific project from 2024 [18, 19] - Revenue from technology-driven contracts increased by 736% year-on-year [21, 22] - The company is targeting technology-driven contracts to reach nearly 50% share [17, 90] Regional Performance - Revenue in Hong Kong & Macau increased by 163% [37] - Gross profit in Hong Kong & Macau decreased by 143% [37] - Revenue in Chinese Mainland decreased by 88% [47] - Gross profit margin in Chinese Mainland increased by 25 percentage points [47, 49] Financial Strategy - Average financing cost decreased by 039 percentage points to 315% [30] - The company aims to turn "Balance" Net Cash Flow positive before 2030 [90]

Financial Performance - Q2 2025 - Sales increased by 3% to $968 million compared to Q2 2024[11] - Gross profit increased by 14% compared to Q2 2024[11] - EBITDA increased by 19.3% compared to Q2 2024[10] - Net loss improved by $47 million, from -$54 million to -$8 million[12] Financial Performance - H1 2025 - Sales decreased by 2.2% to $1,845 million compared to H1 2024[14] - Gross profit increased by 8.2% compared to H1 2024[14] - EBITDA increased by 19.9% compared to H1 2024[10] - Net profit was $22 million, compared to a loss of $69 million in H1 2024[14] - Free cash flow increased by $24 million to $32 million compared to $8 million in H1 2024[10] Regional Performance - North America sales increased by 25% in Q2 and 20% in H1 at CER[17, 17] - Latin America sales increased by 6% in Q2 but decreased by 4% in H1 at CER[18, 18] - Asia Pacific sales decreased by 14% in both Q2 and H1 at CER[20, 20]

Financial Performance - Core profit increased by 1.4% year-over-year to RMB 2,736 million [3] - Operating cash flow increased by 15.7% year-over-year to RMB 5,573 million [3] - The company plans a cash dividend per share of not less than RMB 1.14 in 2025 [4] - The company plans an annual cash dividend payout ratio of not less than 50% of the core profit attributable to the parent company for the year from 2026 to 2028 [4] Natural Gas Business Expansion - Total gas sales volume increased by 6.4% to 20.33 billion cubic meters [2, 34] - Medium- and long-term demand locked in 3.4 billion cubic meters [2] - Zhoushan LNG Terminal unloading volume reached 1.137 million tons, with a year-over-year increase of 11.7% [3, 59] - Newly signed Long-Term Agreement (LTA) with ADNOC for 1 million tons per year [3, 56] Resource Acquisition and Optimization - China's LNG imports in 1H2025 decreased by 20.6% year-over-year to 30.11 million tons [54] - Executed 1.654 billion cubic meters of LTA with CNPC in 1H 2025, a year-over-year increase of 123 million cubic meters [56] - Unconventional resource supplies from various partners reached 1.1 billion cubic meters, a year-over-year increase of over 400 million cubic meters [56] Integrated Energy and Smart Home Business - Integrated Energy sales volume reached 324.5 MW [72] - Intelligent Product Contracts reached RMB 553 million, an 81% year-over-year increase [77]

2025 Interim Results —Resilience and Innovation August 2025 Cautionary Statements Regarding Forward-Looking Statements To the extent any statements made in this Report contain information that is not historical, these statements are essentially forward-looking. These forward-looking statements include but are not limited to projections, targets, estimates and business plans that the Company expects or anticipates may or may not occur in the future. Words such as "potential", "estimates", "expects", "anticip ...

Business Overview & Highlights - 科伦博泰是一家致力于肿瘤学、免疫学和其他治疗领域新药的开发、制造和商业化的生物制药公司[13] - 截至2025年6月30日，公司有30多个在研药物，其中4个处于临床阶段，3款产品上市，5个NDA申请已提交[18] - 全球首款获批上市的治疗肺癌的TROP2 ADC药物Sac-TMT (SKB264/MK-2870)已上市[20] Commercialization - 2025年上半年，商业销售总额达3.098 亿元人民币，其中Sac-TMT (佳泰莱®)销售占比为97.6%[51] - 公司已与多家头部商业集团及零售连锁建立稳定合作关系，其中包含60+家一级经销商及400+家DTP药房[56] - 2025年上半年，佳泰莱®已完成29个省挂网，科泰莱®已完成25个省挂网，达泰莱®已完成15个省挂网[59] Financial Performance - 2025年上半年，公司收入为9.50445亿人民币，毛利为6.59988亿人民币[83, 92] - 2025年上半年，公司研发费用为6.11539亿人民币[86, 92] - 截至2025年6月30日，公司现金及现金等价物为31.02792亿人民币[89, 94]

Financial Performance - The Group's revenue reached RMB 131,867 million, a YoY increase of 2.5%[11] - Gross profit increased to RMB 21,510 million, representing a YoY growth of 2.8%[11] - Net profit attributable to shareholders decreased significantly by 20.3% to RMB 2,077 million[11] - Operating cash flow significantly improved, reaching RMB 1,531 million, a YoY increase of 250.1%[11] Business Segments - Pharmaceutical manufacturing business revenue increased by 4.3% YoY to RMB 24.81 billion[20] - Distribution business revenue increased by 2.3% YoY to RMB 108,330 million[63] - Retail business revenue increased by 11.4% YoY to RMB 5,515 million[63] Strategic Initiatives - The Group completed the acquisitions of Nigale and Tasly to expand into medical devices and TCM, respectively[24] - The Group is committed to innovative R&D with 476 total projects under research and development[37] - The Group is strengthening international expansion of chemical drugs, TCM, medical devices and blood products[54] - The Group introduced 7 new medical device products, with estimated annual revenue contribution of over RMB 600 million[73]

Overall Results - Operating revenue稳步增长，从2022年上半年的1763亿人民币增长到2025年上半年的2002亿人民币[7] - Service revenue稳步增长，从2022年上半年的1610亿人民币增长到2025年上半年的1784亿人民币[7] - 除所得税前的利润从2022年上半年的134亿人民币增长到2025年上半年的178亿人民币[7] Business Structure - Connectivity and Communications (CC)业务收入为1319亿人民币[10] - Computing and Digital Smart Applications (CDSA)业务收入为454亿人民币[10] - 国际业务收入为68亿人民币，同比增长111%[10] - CC业务占总服务收入的74%，CDSA业务占26%[10] Subscriber Base - 移动和宽带用户净增在近几年达到新高，总用户达到480 million[15] - 物联网连接数净增6032万，总连接数达到690 million[15] Subscriber Value - 云AI产品用户达到270 million，净增超过20 million[18] - “双千兆”用户比例达到50%[18] Computing Power Business - Unicom Cloud收入从2024年上半年的359亿人民币增长到2025年上半年的376亿人民币[24] - 数据中心收入从2024年上半年的131亿人民币增长到2025年上半年的144亿人民币[24] Network Investment - CAPEX为550亿人民币，同比下降15%[35] Financial Risk Control - 带息债务从2024年12月的4121亿人民币减少到2025年6月的3684亿人民币，下降XXX%[56] - 资产负债率从2024年12月的458%下降到2025年6月的437%[58] Shareholder Returns - 董事会决议派发中期股息每股02841人民币（税前），同比增长145%[47]

Financial Performance - The Group's OPAT increased by 2.4% year-over-year to RMB 37.9 billion[7, 15] - Net profit decreased by 26.4% year-over-year to RMB 27.0 billion[7, 16] - Life & Health (L&H) OPAT rose 5.0% year-over-year to RMB 26.9 billion[13] - Basic operating EPS rose 3.3% year-over-year to RMB 2.16[13] Business Growth - New Business Value (NBV) for L&H increased significantly by 34.9% year-over-year to RMB 12.9 billion[7, 14, 25] - L&H NBV margin (ANP basis) improved by 10.4 percentage points to 32.0%[7, 26] - The Property & Casualty (P&C) combined operating ratio (COR) improved by 3.0 percentage points year-over-year to 96.6%[7, 11, 31] - P&C insurance revenue increased by 0.7% year-over-year to RMB 81.153 billion[31] - Bank net profit decreased by 5.6% year-over-year to RMB 14.1 billion[12, 35] Customer Base - The Group's retail customer base grew by 1.0% year-to-date to 245 million[7, 13, 18] - The retention rate of retail customers holding 4 or more contracts within the Group was 98.0%[13] Channel Development - Bancassurance channel NBV soared 170.8% year-over-year[14, 29] - Community finance channel NBV surged 171.3% year-over-year[14, 29] Solvency - The company's solvency ratios are well above the minimum regulatory requirements[36, 37]